LAW OFFICES OF

JACOBSON HOLMAN

PROFESSIONAL LIMITED LIABILITY COMPANY

400 SEVENTH STREET, N. W.

WASHINGTON, D. C. 20004

(202) 638-6666

JACOBSON HOLMAN STERN

OF COUNSEL MARVIN R. STERN NATHANIEL A. HUMPHRIES

TELEFAX: (202) 393-5350 (202) 393-535 ((202) 393-5352

E-MAIL: IP@JPHS.COM INTERNET: WWW.JPHS.COM *BAR OTHER THAN DC

> Writer's Direct Dial (202) 662-8497 SSundby@JHIP.com

24 September 2001

Commissioner for Patents Washington, D.C. 20231

Box Patent Application



Dear Sir:

HARVEY B. JACOBSON, JR.
JOHN CLARKE HOLMAN
SIMOR L. MOSKOWITZ
ALLEN S. MELSER
MICHAEL R. SLOBASKY
HARBA G. GENTNER
DOTATHAN L. SCHERER
MICHAEL R. SLOBASKY
MICHAEL R.

This is a request for filing a Continuation, Divisional, or Continuation-in-Part under 37 C.F.R 1.53(b) of the prior utility patent application Serial No. 09/523,271, filed on March 10, 2001, entitled Deglycosylated Ricin Toxin A-Chain Vaccine, by the following inventor(s):

Robert W. Wannemacher 5607 Calvert Drive Frederick, Maryland 21703 John F. Hewetson 126 Kline Boulevard Frederick, Maryland 21701

The Examiner of the prior application is **J. Roark** and the Group Art Unit of the prior application is **1644**.


The Attorney Docket No. for the present application is **P66821US2** (RIID 99-12).

I. Application Elements:

4		4	. 1
	Dra	11122112217	Amendmen
1 .	110	annininai v	

- a. A Preliminary Amendment is enclosed (includes amendment to cross reference to related applications).
- b. Please amend the specification by inserting after the first paragraph, the following:

9.



2. The filing fee has been calculated on the basis of the claims existing in the prior application as amended at 1 above.

(Col. 2)
i No. Extra
3
2
•

^{*}If the difference in Col. 1 is less than zero, enter "0" in Col. 2

SMALL	ENTITY
Rate	Fee
	\$355.00
x 9 =	
x 40=	
+ 135 =	
Total	

LARGI	E ENTITY
Rate	Fee
	\$710.00
x 18 =	\$54.00
x 80 =	\$160.00
+ 270 =	
Total	924.00

or or or or or

or

	3.	Small Entity Status Assertion under 35 U.S.C. 1.27(c)(1):
		Applicant is is is not a Small Entity.
	4.	 Enclosed herewith is a specification containing: (a) 59 pages of description; (b) 3 pages of claims (23 claims); (c) 1 page of Abstract
	5.	Enclosed herewith are 14 sheets of drawings (Figures 1-19).
	6.	Oath or Declaration (a) newly executed (b) Copy from a prior application under 37 C.F.R. 1.63(d) for a continuation or a divisional. i. A signed statement deleting inventor(s) named in the prior application under 37 C.F.R 1.63(d)(2) and 1.33(b) is attached.
	7.	An Application Data Sheet under 37 C.F.R. 1.76 \square is \boxtimes not enclosed.
	8.	Nucleotide and/or Amino Acid Sequence Submission is not enclosed. (a) Computer Readable Form (CFR) of Sequence Listing. (b) Paper copy of Sequence Listing. (c) Statements verifying identity of the above copies.
П.	Enclos	sures:
Office		close the following papers for filing in the United States Patent and Trademark ection with the above-identified patent application.
	8.	Assignment papers.

The prior application is assigned of record to *.

III.

IV.


tember 2	2001 Page 3 of 3
10.	37 C.F.R 3.73(b) Statement (where assignee).
11.	 Power of Attorney: (a) Power of Attorney in the prior application is to Suzannah K. Sundby, Registration No. 43,172. (b) The Power of Attorney is in the original papers of the prior application, or a copy of the Power of Attorney is enclosed. (c) A newly executed Power of Attorney is enclosed.
12.	Enclosed is a copy of the prior application as originally filed, namely Serial No. 09/523,271, filed on March 10, 2000. The entire disclosure of the prior application is hereby incorporated by reference.
13.	☑ Information Disclosure Statement(s) and PTO 1449 which was filed in Serial No. 09/523,271, filed March 16, 2001, February 14, 2001 and August 3, 2000 which is relied on for an earlier filing date under 35 U.S.C. 120.
14.	Copies of IDS citations.
15.	2 return receipt postcards.
Petitic 1	on for Extension of Time A Petition for an Extension of 1 Month(s) is enclosed to extend the life of the above prior application to at least the date hereof is (a) being concurrently filed in that prior application. (b) was previously filed in that application. (c) is not necessary.
2.	☐ If a Petition for an Extension of Time is necessary and the Petition and/or the check is not enclosed, the Applicant hereby petitions the Commissioner to extend the time for response and charge any fees necessary under 37 C.F.R. 1.17(a)(a1)-(5) to Deposit Account No. 210-380, Reference No. P66821US2 (RIID 9912).
Correspondence Address.	
The correspondence address for this application is (37 C.F.R. §1.51(vii)):	
	Office of the Staff Judge Advocate U.S. Army Medical Research and Materiel Command ATTN: MCMR-JA (Ms. Elizabeth Arwine) 504 Scott Street

Fort Detrick, MD 21702-5012

V. Statement as to whether invention was made by an agency of the U.S. Government or under contract with an agency of the U.S. Government. (37 C.F.R. §1.51(viii)):

This invention was made by the United States Army Medical Research and Materiel Command, which is an agency of the United States Government.

	Co	ommand, which is an agency of the United States Government.		
VI.	Clain	Claim for Priority:		
	16.	Foreign priority benefits under 35 U.S.C. 119(a)-(d) is hereby claimed of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:		
		Foreign Application: Country: Filing Date:		
	17.	The benefit of priority under 35 U.S.C. 119(e) is hereby claimed of the United States provisional patent application(s) listed below:		
		Serial No.: 60/124,283 Filing Date: March 12, 1999 Status: Pending		
	18.	The benefit of priority under 35 U.S.C. 120 is hereby claimed of any United States non-provisional patent application(s) listed below:		
		Serial No.: 09/523,271 Filing Date: March 10, 2000 Status: Pending		
VI.	Meth	od of fee payment		
	19. 20. 21.	☐ A Check in the amount of is enclosed. ☐ Charge Account No. 210-380, Reference No. P66821US2 (RIID 9912) in the amount of \$924.00. ☐ The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 210-380. A duplicate copy of this sheet is		
		 attached. (a) Any additional filing fees required under 37 C.F.R. §1.16. (b) Any patent application processing fees under 37 C.F.R. §1.17. (c) If the Filing Fee is found to be insufficient for any reason, please charge such deficiency to Deposit Account No. 210-380, Reference No. P66821US2 (RIID 9912). 		



Respectfully submitted,

JACOBSON HOLMAN, RLLC

Suzannah K. Sundby

Reg. No. 43,172

Date: 24 September 2001